Coronation Fund Managers Ltd. Has $35.10 Million Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Coronation Fund Managers Ltd. increased its stake in Thermo Fisher Scientific Inc. by 22.4%, owning 86,558 shares valued at approximately $35.1 million, which is 1.9% of its investment portfolio.
• Thermo Fisher reported earnings of $5.36 per share for the last quarter, exceeding analyst expectations of $5.22, with a total revenue of $10.86 billion.
• Institutional investors now own over 89% of Thermo Fisher's stock, indicating strong backing from large investment firms.

Coronation Fund Managers Ltd. raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 22.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 86,558 shares of the medical research company's stock after buying an additional 15,841 shares during the period. Thermo Fisher Scientific comprises about 1.9% of Coronation Fund Managers Ltd.'s investment portfolio, making the stock its 16th biggest holding. Coronation Fund Managers Ltd.'s holdings in Thermo Fisher Scientific were worth $35,096,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC lifted its stake in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Thermo Fisher Scientific by 22.0% in the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after purchasing an additional 877 shares during the last quarter. PFG Investments LLC lifted its stake in shares of Thermo Fisher Scientific by 4.0% in the 1st quarter. PFG Investments LLC now owns 2,222 shares of the medical research company's stock valued at $1,106,000 after purchasing an additional 86 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. lifted its stake in shares of Thermo Fisher Scientific by 1.8% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 38,154 shares of the medical research company's stock valued at $18,986,000 after purchasing an additional 691 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $544.02 on Tuesday. The stock has a market cap of $205.43 billion, a P/E ratio of 31.46, a PEG ratio of 2.93 and a beta of 0.77. The company's 50-day simple moving average is $497.37 and its 200 day simple moving average is $449.73. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Robert W. Baird lifted their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Weiss Ratings reiterated a "hold (c)" rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. William Blair started coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating on the stock. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, October 12th. Finally, Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, October 8th. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $589.10.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the company's stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares of the company's stock, valued at approximately $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 over the last quarter. 0.33% of the stock is owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.